In india, the market for sitag liptin and its combinations makes up ten % of the oral anti dibetes drug market. murk has a patent on the molecule, which means you can't market the drug under your own bran name,. unless you strike a bargain with murk. In 20 15, another popular diabetic compound, tenely glipton, lost its patent. And guess what happened? Over one point eight five million switch to generic varient. With at least four more such patents on diabetic compounds set to expire by 20 25, the looming entry of generics could provide much needed relief. It can sing handedly make diabetic therapy more affordable for